Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab extension study for acute gouty arthritis flares
NCT01431638Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2011
- Primary completion
- May 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in acute gouty arthritis, sponsored by Novartis. Primary endpoint: Number of Participants Who Reported Adverse Events at 48 weeks. Started Aug 2011; status: completed.
02
Drugs
canakinumab
03
Conditions
acute gouty arthritis
Beyond the preview
Go deeper on NCT01431638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01431638.